BRVE — Braveheart Bio, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 2131524 ·
Last close
$18.78
Market Cap
$1.69B
52W High
$32.00
52W Low
$16.70
ADV30
408,433
Next earnings
2026-11-10
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -30,149,000 -26,495,000 514,450,000 121,291,000 16,848,000
Jun 2026 0 — -15,882,000 -14,988,000 126,956,000 122,831,000 222,862,000
Mar 2026 0 — -15,049,000 -14,280,000 81,878,000 80,576,000 160,270,000
Dec 2025 0 — -6,982,000 -6,454,000 89,350,000 89,161,000 155,222,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-47,783,000
Investing CF
$-386,313,000
Financing CF
$487,855,000
CapEx
$-3,871,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.52
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-122,402,000
Inventory
—
Receivables
—
ST Investments
$227,981,000
EBIT TTM
$-68,062,000
Pretax Income TTM
$-62,217,000
Interest Exp TTM
—
Analysts
4

Annual Trend (SEC EDGAR, last 1y)

Revenues vs Net Income (last 1y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -4,505,000 -66,052,000 89,350,000 155,222,000 -65,872,000 -2,014,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$126,956,000
Forward EPS
$-1.99

Peers — same industry

TickerNameMarket CapLastDaily %
SUPN Supernus, Inc. $1.69B $29.04 —
SDGR Schrodinger, Inc. $1.68B $25.66 —
RARE Ultragenyx Pharmaceutical Inc. $1.70B $16.70 —
STOK Stoke Therapeutics, Inc. $1.73B $26.41 —
ZYME Zymeworks Inc. $1.78B $25.84 —

News headlines (Yahoo Finance, 1h cache)

Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-10 21:03 · Yahoo
Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London
2026-11-09 12:30 · Yahoo
Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial
2026-11-07 01:14 · Yahoo
Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Se
2026-11-06 20:15 · Yahoo
Where Does Braveheart Bio (BRVE) Value Sit After AHA Data?
2026-11-05 06:14 · Yahoo
Braveheart Bio (BRVE), Why Is Attention Building Around It?
2026-11-04 10:20 · Yahoo
Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026
2026-10-30 11:30 · Yahoo
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
2026-10-30 11:30 · Yahoo
Braveheart Bio to Participate in Stifel Cardiometabolic Forum
2026-09-16 20:30 · Yahoo
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-09-08 20:03 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.